Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-28

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has demonstrated significant anti-tumor activity in certain cancer. The goal of this study was to evaluate the efficacy and safety of sintilimab (a human programmed death-1 ICI) plus anlotinib (a multi-target tyrosine kinase inhibitor, inhibiting tumor angiogenesis and proliferative signaling) in advanced non clear cell renal cell carcinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

NCT05124431

Renal Cell Carcinoma

UNKNOWN PHASE2

Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

NCT00706706

Carcinoma, Renal Cell

COMPLETED PHASE4

A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer

NCT04958473

Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma

UNKNOWN PHASE2

A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

NCT02626754

Renal Cell Carcinoma

TERMINATED PHASE2

Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

NCT07024680

Papillary Renal Cell Carcinoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Clear Cell Renal Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anlotinib plus Sintilimab

Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle) .Sintilimab was administered intravenously (200mg once every 3weeks).

Group Type OTHER

Anlotinib plus Sintilimab

Intervention Type DRUG

Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anlotinib plus Sintilimab

Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects voluntarily joined the study and signed informed consent;
* Aged \> 18 years;
* ECOG body status score is 0 or 1,Expected survival time is greater than 3 months.
* Locally advanced or metastatic, histological confirmed, non-clear cell RCC of all subtypes. Patients must have advanced non-clear cell of one of the following subtypes: papillary, chromophobe, collecting duct carcinoma (CDC), renal medullary carcinoma (RMC), or unclassified.
* Patients must have measurable lesions as defined by the RECIST 1.1 standard;
* Adequate hematologic and end-organ function as defined by the following laboratory results obtained within 28 days prior to the first study treatment:

1. Absolute neutrophil count (ANC) ≥1.5x 109/L
2. Lymphocyte count ≥ 500/uL.
3. Platelet count ≥ 80x109/L.
4. Hemoglobin ≥ 80 g/L (patients may be transfused to meet this criterion).
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) with the following exceptions: Patients with documented liver/bone metastases should have AST and ALT ≤ 5 x ULN.
6. Serum bilirubin ≤ 1.5 x ULN.
7. Creatinine clearance ≥ 60 mL/min.
8. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective forms of contraception and to continue its use 4 weeks after the last dose of anlotinib or sintilimab.
* Signed informed consent form.
* Ability and capacity to comply with study and follow-up procedures.

Exclusion Criteria

* Those who are known to be allergic to pharmaceutical ingredients.
* Receive anti-tumor monoclonal antibody or other research drugs within 4 weeks before enrollment; have received other anti-PD-1 antibody therapy or other treatment for PD-1/PD-L1;
* Previous use of anlotinib or other angiogenesis inhibitors
* The patient has any active autoimmune disease or a history of autoimmune disease;
* There are uncontrolled heart clinical symptoms or diseases;
* Patients with congenital or acquired immune deficiency;
* Receive chemotherapy, targeted therapy, radiotherapy within 2 weeks before enrollment;
* A history of gastrointestinal perforation or major surgery within 4 weeks before enrollment;
* Overactive/venous thrombosis occurred within 6 months prior to enrollment, such as cardiovascular-cerebral vascular (including transient ischemic attack),deep vein thrombosis (except for patients who have recovered from venous catheterization due to previous chemotherapy)and pulmonary embolism;
* Those with active bleeding or bleeding tendency;
* Presence of a drug uncontrolled hypertension;
* Urine routine indicates more than urinary protein 2+;
* Correct QT interval \> 470msec; if the patient has a prolonged QT interval, but the investigator's study evaluates that the prolongation is due to a cardiac pacemaker (and no other abnormalities in the heart), it is necessary to discuss with the sponsor's researcher to determine if the patient is Suitable for group study;
* Patients suspected of having other primary cancers;
* Those who are known to be allergic to pharmaceutical ingredients.
* Patients with active or chronic hepatitis B (defined as having a positive hepatitis B surface antigen \[HBsAg\] test at screening). Patients with past/resolved HBV infection (defined as having negative HBsAg test and a positive antibody to hepatitis B core antigen \[anti-HBc\] antibody test) are eligible. A negative HBA DNA test must be obtained in patients with positive hepatitis B core antibody prior to Cycle 1 Day 1.
* Active hepatitis C infection. Patients positive hepatitis C antibody test are eligible if PCR is negative for hepatitis C viral DNA.
* Pregnant or lactating women.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No